Cannabis products: medical use

Oral CBD-rich cannabis induces clinical but not endoscopic response in patients with Crohn's disease, a randomized controlled trial

(2021) Timna Naftali et al.   Journal of Crohns & Colitis

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome

(2020) Ian Miller et al.   JAMA Neurology

Add-On Cannabidiol Treatment for Drug-Resistant Seizures in Tuberous Sclerosis Complex

(2020) Elizabeth A. Thiele et al.   JAMA Neurology

RoB 2: a revised tool for assessing risk of bias in randomised trials

(2019) Jonathan A C Sterne et al.   BMJ-British Medical Journal

Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial

(2018) Philip McGuire et al.   AMERICAN JOURNAL OF PSYCHIATRY

Sativex® as Add-on therapy Vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical trial

(2018) Jolana Markovà et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Results of a Double-Blind, Randomized, Placebo-Controlled Study of Nabiximols Oromucosal Spray as an Adjunctive Therapy in Advanced Cancer Patients with Chronic Uncontrolled Pain

(2018) Aron H. Lichtman et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

(2018) Orrin Devinsky et al.   NEUROLOGY

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial

(2018) Douglas L. Boggs et al.   PSYCHOPHARMACOLOGY

The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial

(2018) Jenny G. Turcott et al.   SUPPORTIVE CARE IN CANCER

Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients

(2017) Sebastian Schimrigk et al.   EUROPEAN NEUROLOGY

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Cannabinoids in the Treatment of Chemotherapy-Induced Nausea and Vomiting

(2017) Barbara Todaro   Journal of the National Comprehensive Cancer Network

Intravenous Delta-9-Tetrahydrocannabinol to Prevent Postoperative Nausea and Vomiting

(2015) Maren Kleine-Brueggeney et al.   ANESTHESIA AND ANALGESIA

The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

(2015) Susan Ball et al.   HEALTH TECHNOLOGY ASSESSMENT

A double-blind, randomized, placebo-controlled, parallel group study of THC/CBD spray in peripheral neuropathic pain treatment

(2014) M. Serpell et al.   EUROPEAN JOURNAL OF PAIN

Cannabis Induces a Clinical Response in Patients With Crohn's Disease: A Prospective Placebo-Controlled Study

(2013) Timna Naftali et al.   Clinical Gastroenterology and Hepatology

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

(2013) John Zajicek et al.   LANCET NEUROLOGY

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis

(2012) R. M. Langford et al.   JOURNAL OF NEUROLOGY

MUltiple Sclerosis and Extract of Cannabis: results of the MUSEC trial

(2012) John Peter Zajicek et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Nabiximols for Opioid-Treated Cancer Patients With Poorly-Controlled Chronic Pain: A Randomized, Placebo-Controlled, Graded-Dose Trial

(2012) Russell K. Portenoy et al.   JOURNAL OF PAIN

An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain

(2012) Cory Toth et al.   PAIN

Delta-9-tetrahydrocannabinol may palliate altered chemosensory perception in cancer patients: results of a randomized, double-blind, placebo-controlled pilot trial

(2011) T. D. Brisbois et al.   ANNALS OF ONCOLOGY

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis

(2011) A. Novotna et al.   EUROPEAN JOURNAL OF NEUROLOGY

Preliminary efficacy and safety of an oromucosal standardized cannabis extract in chemotherapy-induced nausea and vomiting

(2010) Marta Duran et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis

(2010) RBC Kavia et al.   Multiple Sclerosis Journal

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis

(2010) C. Collin et al.   NEUROLOGICAL RESEARCH

Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a major confounding factor

(2009) D. Selvarajah et al.   DIABETES CARE

Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract and THC Extract in Patients with Intractable Cancer-Related Pain

(2009) Jeremy R. Johnson et al.   JOURNAL OF PAIN AND SYMPTOM MANAGEMENT